Nelson, Van Denburg & Campbell Wealth Management »

Allogene Therapeutics shares owned by Nelson, Van Denburg & Campbell Wealth Management

Quarter-by-quarter ownership of Allogene Therapeutics (ALLO) shares owned by Nelson, Van Denburg & Campbell Wealth Management from 13F filings

Historical chart of Nelson, Van Denburg & Campbell Wealth Management investment in Allogene Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Allogene Therapeutics held by Nelson, Van Denburg & Campbell Wealth Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Allogene Therapeutics by Nelson, Van Denburg & Campbell Wealth Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $6.7k 1.5k 4.47
2023-12-31 $4.7k 1.5k 3.21

More positions owned by Nelson, Van Denburg & Campbell Wealth Management

Ishares Core Dividend Growth Etf Etf (DGRO)
Vanguard Growth Etf Etf (VUG)
Vanguard Index Fds Mid-cap Value Index Viper Shs Etf Etf (VOE)
Vanguard Mid Cap Growth Etf Etf (VOT)
Ishares S&p 500 Index Etf (IVV)
Berkshire Hathaway Inc Del Cl B Stock (BRK.B)
Jpmorgan Active Value Etf Etf (JAVA)
Vanguard Ftse Developed Markets Etf Etf (VEA)
Apple Stock (AAPL)
Vanguard S&p 500 Etf Etf (VOO)
Jpmorgan Active Growth Etf Etf (JGRO)
Spdr Ser Tr Dj Wilshire Small Cap Value Etf Etf (SLYV)
Microsoft Stock (MSFT)
Schwab Us Large Cap Growth Etf Etf (SCHG)
Ishares Morningstar Mid-cap Growth Etf Etf (IMCG)

View all positions for Nelson, Van Denburg & Campbell Wealth Management

Top funds holding Allogene Therapeutics

Tpg Gp A
Vanguard Group
Jpmorgan Chase & Co
PRIMECAP Management Company
Citadel Advisors
Goldman Sachs Group
T. Rowe Price Associates
Two Sigma Investments
Millennium Management
Vida Ventures Advisors
Dimensional Fund Advisors
Two Sigma Advisers
Caxton Associates
Nordea Investment Management Ab
Charles Schwab Investment Management

View all funds holding Allogene Therapeutics